



WORLD HEALTH ORGANIZATION

First Global Consultation on
Regulatory Requirements for
Human Cells and Tissues for Transplantation

Ottawa, 29 November to 1 December 2004

Report

WHO Library Cataloguing-in-Publication Data

Global Consultation on Regulatory Requirements for Human Cells and Tissues for Transplantation (1st : 2004 : Ottawa, Canada)

First Global Consultation on Regulatory Requirements for Human Cells and Tissues for Transplantation, Ottawa, 29 November to 1 December 2004 : report.

1. Cell transplantation – legislation 2. Tissue transplantation – legislation 3. Cell legislation – standards 4. Tissue transplantation – standards I. Title.

ISBN 92 4 159329 6

(NLM classification: WO 690)

© World Health Organization 2005

All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel: +41 22 791 2476; fax: +41 22 791 4857; email: bookorders@who.int). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; email: permissions@who.int).

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either express or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

Printed by the WHO Document Production Services, Geneva, Switzerland

Report

First Global Consultation on
Regulatory Requirements for
Human Cells and Tissues for Transplantation

Ottawa, 29 November to 1 December 2004

Introductory Note from the Secretariat

This publication reports on the deliberations and outcomes of the first Global Consultation on Regulatory Requirements for Human Cells and Tissues for Transplantation, held in Ottawa from 29 November to 1 December 2004. The Ottawa meeting represents the first step in WHO involvement in harmonizing global practices in the procurement, processing and transplantation of human cells and tissues, along the requirements of World Health Assembly Resolution WHA57.18 on Human Organ and Tissue Transplantation adopted in May 2004.

This meeting was made possible thanks to the support of the Canadian Ministry of Health, through Health Canada and the Public Health Agency of Canada. We gratefully acknowledge this aid and, in particular, we wish to thank the staff of these two organizations for their efficient assistance in preparing and supporting the consultation.

This report represents the views of the participants, not necessarily those of WHO. The report was prepared by the undersigned with the efficient administrative and secretarial support of Christine Faivre-Pierret. It is based on a draft prepared by the meeting Rapporteurs, Deirdre Fehily and Jill Hartzler-Warner, with the assistance of Martha Wells, who deserve thanks for their dedication and their success at capturing and summarizing complex material with clarity. Deirdre Fehily also played an important role in the preparation of this consultation and her input is gratefully acknowledged. All the participants in the consultation should be thanked for their active participation and their will to achieve consensus. The Secretariat owes special thanks to the Chairman of the meeting, Elwyn Griffiths, for his steady and thoughtful chairmanship.

The report was submitted to all participants for comment. We are grateful to them for their input. Any error or omissions are, of course, our responsibility, not theirs.

Luc Noël, Coordinator, HTP/EHT/CPR

Table of contents

EXECUTIVE SUMMARY	1
OPENING SESSION.....	3
SESSION 1: INTRODUCTION	4
OBJECTIVES, SCOPE AND EXPECTED OUTCOMES FOR THE CONSULTATION	6
CELL AND TISSUE REGULATORY OVERSIGHT – THE EXAMPLE OF CANADA	7
SESSION 2: GLOBAL ISSUES IN CTTX.....	10
US REGULATORY OVERSIGHT AND SURVEILLANCE OF HUMAN CELLS AND TISSUES	18
SESSION 3: SAFETY AND SURVEILLANCE IN CTTX.....	21
CELLS, TISSUES, AND ORGANS USED IN TRANSPLANTATION: ADVERSE EVENT MONITORING AND SURVEILLANCE SYSTEM	21
THE NEW US ADVERSE EVENT MONITORING SYSTEM.....	22
TOWARDS A GLOBAL KNOWLEDGE DATABASE ON RISKS AND SAFETY MEASURES FOR INFECTIONS ASSOCIATED WITH HUMAN MATERIAL FOR THERAPEUTIC USE	22
DISCUSSION AND SUMMARY OF DAY 1	24
SESSION 4: CTTX: ESSENTIALS FOR GOOD PRACTICE, GOVERNANCE AND OVERSIGHT.....	24
THE ROLE OF NATIONAL HEALTH AUTHORITIES IN ENSURING ACCESS TO SAFE, EFFECTIVE AND QUALITY TISSUES AND CELLS: THE FRENCH EXPERIENCE	24
ESSENTIAL PROCESS REQUIREMENTS FOR CELL AND TISSUE TRANSPLANTATION FROM PROCUREMENT TO FOLLOW UP OF RECIPIENTS	26
SESSION 4: DISCUSSION.....	30
SESSION 5: CROSS-CUTTING SPECIFICATIONS FOR CELLS AND TISSUES FOR TRANSPLANTATION	31
NORMATIVE WORK AT WHO	31
CROSS-CUTTING SPECIFICATIONS – THE CANADIAN STANDARDS	33
DEFINITION AND CLASSIFICATION OF CTTX	34
PROPOSED METHOD FOR GLOBAL SPECIFICATIONS FOR BASIC TISSUES AND CELLS.....	36
SESSION 6: CORE SPECIFICATIONS FOR ESSENTIAL CTTX.....	38
SESSION 7: ACCESS AND INTERNATIONAL CIRCULATION OF CTTX	39
CORNEAS.....	40
HEART VALVES	40
DISTRIBUTION OF TISSUES BY US BANKS TO OTHER COUNTRIES	41
SESSION 8: NEXT STEPS.....	43
CELLS AND TISSUES FOR TRANSPLANTATION: FROM BASIC TO BIOTECH – THE AUSTRALIAN REGULATORY APPROACH.....	43
FUTURE WORK AND CONCLUSIONS	44
APPENDIX 1	46
WORLD HEALTH ASSEMBLY RESOLUTION WHA57.18 (MAY 2004)	46
APPENDIX 2	49
WHO DRAFT TISSUE AND CELL PRODUCT LIST	49
APPENDIX 3	58
DOCUMENTS INCLUDED IN THE REVIEW	58
APPENDIX 4	60
LIST OF PARTICIPANTS	60
APPENDIX 5	65
PROGRAMME OF WORK	65

Executive Summary

Cells and tissues for transplantation (CTTx) constitute a specific class of health products with important therapeutic value, as they have in many cases no equivalent in restoring life-supporting or essential functions. Yet many countries have poor access to essential CTTx, such as cornea. At national level in most countries CTTx activity data is not available. Many countries are lacking regulatory frameworks for CTTx despite the inherent disease transmission risks associated with the transplantation of human material. Many CTTx are circulating across international boundaries to meet patient needs, in physical or immunological characteristics, or simply to bridge a supply gap. A large proportion of these CTTx circulate outside of any regulatory oversight.

World Health Assembly Resolution WHA 57.18 urges Member States to "implement effective national oversight of procurement, processing and transplantation of human cells, tissues and organs, including ensuring accountability for human material for transplantation and its traceability". The development of regulations and planning for CTTx services are the responsibility of health authorities in order to ensure protection of the donor, patient safety and clinical efficacy. Beyond outcomes for the donor and the recipient, current developments in the area of cellular therapy and tissue engineering need to progress in a clear regulatory environment. The benefits of implementing a comprehensive regulatory framework outweigh the cost of the necessary investment.

A comprehensive regulatory framework encompasses defining a system of reference, such as standards, providing specifications for CTTx which should be legally mandated, a system for ensuring compliance and enforcement, surveillance system and accreditation. It is important that regulation address public and private activities alike. Both should be associated with the process of reaching an agreement on requirements and best practices, in particular through the input of professional societies and all stakeholders.

Requirements for CTTx must balance high quality with the need to ensure availability and must not limit innovation or serve as a barrier to international exchanges.

Participants in the consultation examined first drafts of core global specifications for basic essential tissue and cell products that are used globally and are moved between countries or marketed commercially (frozen bone or tendon, freeze-dried bone, skin, amniotic membrane, cryopreserved cardiac valves and vascular segments, cornea, fresh haematopoietic stem cells, cryopreserved allogeneic unrelated cord blood stem cells and cryopreserved

预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_24485

